ReviewBiosensors2021
Multi-Functionalized Nanomaterials and Nanoparticles for Diagnosis and Treatment of Retinoblastoma.
Review in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 74 citations in OpenAlex.
- Nanotherapeutic potential in glaucoma associated ocular cancers.Discover oncology · 2026Review
- A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma.Diseases (Basel, Switzerland) · 2025Review
- Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discover nano · 2025Review
- LIFU (Low-Intensity Focused Ultrasound) Activated Tumor-Starvation/Oxidative-Stress Combined Therapy for Treating Retinoblastoma.International journal of nanomedicine · 2025Article
- Biosynthesis of sulfur quantum dots and cerium oxide nanoparticles for bioimaging and reactive oxygen species modulation in Y79 retinoblastoma cancer cells.BioImpacts : BI · 2025Article
- Green synthesis of Zn-doped TIOBMC plant biology · 2024Article
- New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB.Molecular oncology · 2024Article
- Preparation of a Novel Multifunctional Cationic Liposome Drug-carrying System and its Functional Study on Lung Cancer.Anti-cancer agents in medicinal chemistry · 2024Article
- Recent Breakthroughs in Using Quantum Dots for Cancer Imaging and Drug Delivery Purposes.Nanomaterials (Basel, Switzerland) · 2023Review
- Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects.Nanoscale advances · 2023Review
- Recent Advances in Nanotechnology for the Management ofBiosensors · 2022Review
- Review
- Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.Journal of nanobiotechnology · 2022Review
- Fabrication of α-FeACS omega · 2022Article
- Effects of folate-conjugated FeMedical oncology (Northwood, London, England) · 2022Article
- Electrochemical Sensor Based on Glassy-Carbon Electrode Modified with Dual-Ligand EC-MOFs Supported on rGO for BPA.Biosensors · 2022Article
- Advance Nanomaterials for Biosensors.Biosensors · 2022Article
- Nucleic Acids and Their Analogues for Biomedical Applications.Biosensors · 2022Review
- Cytotoxicity properties of plant-mediated synthesized K-doped ZnO nanostructures.Bioprocess and biosystems engineering · 2022Article
- Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.Journal of drug delivery science and technology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma is a rare type of cancer, and its treatment, as well as diagnosis, is challenging, owing to mutations in the tumor-suppressor genes and lack of targeted, efficient, cost-effective therapy, exhibiting a significant need for novel approaches to address these concerns. For this purpose, nanotechnology has revolutionized the field of medicine with versatile potential capabilities for both the diagnosis, as well as the treatment, of retinoblastoma via the targeted and controlled delivery of anticancer drugs via binding to the overexpressed retinoblastoma gene. Nanotechnology has also generated massive advancements in the treatment of retinoblastoma based on the use of surface-tailored multi-functionalized nanocarriers; overexpressed receptor-based nanocarriers ligands (folate, galactose, and hyaluronic acid); lipid-based nanocarriers; and metallic nanocarriers. These nanocarriers seem to benchmark in mitigating a plethora of malignant retinoblastoma via targeted delivery at a specified site, resulting in programmed apoptosis in cancer cells. The effectiveness of these nanoplatforms in diagnosing and treating intraocular cancers such as retinoblastoma has not been properly discussed, despite the increasing significance of nanomedicine in cancer management. This article reviewed the recent milestones and future development areas in the field of intraocular drug delivery and diagnostic platforms focused on nanotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.